AEGR-733

From Self-sufficiency
Jump to: navigation, search
AEGR-733
File:AEGR-733 structure.svg
Systematic (IUPAC) name
N-(2,2,2-Trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]9H-fluoren-9-carboxamde
Clinical data
Routes of
administration
oral
Legal status
Legal status
  • investigational
Identifiers
CAS Number 182431-12-5
ATC code none
Chemical data
Formula C39H37F6N3O2
Molar mass 693.719 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

AEGR-773 (previously BMS-201038) is an investigational drug for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals.[1] It has been tested in several Phase II clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate.[2][3]

A Phase III trial has started in December 2007 and will be running until August 2011.[4]

Mechanism of action

AEGR-773 inhibits the microsomal triglyceride transfer protein (MTP or MTTP) which plays a role in lipoprotein assembly and secretion in the liver.[1]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. 1.0 1.1 H. Spreitzer (12 March 2007). "Neue Wirkstoffe – BMS-201038". Österreichische Apothekerzeitung (in German) (6/2007): 268. 
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. Aegerion Pharmaceuticals, Inc. Announces AEGR-733 Phase II Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile
  4. ClinicalTrials.gov NCT00730236 A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)